CN114340623A - 嘧啶并[5,4-b]吡呤化合物的制药用途 - Google Patents

嘧啶并[5,4-b]吡呤化合物的制药用途 Download PDF

Info

Publication number
CN114340623A
CN114340623A CN202080060433.XA CN202080060433A CN114340623A CN 114340623 A CN114340623 A CN 114340623A CN 202080060433 A CN202080060433 A CN 202080060433A CN 114340623 A CN114340623 A CN 114340623A
Authority
CN
China
Prior art keywords
acid
compound
pharmaceutically acceptable
use according
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080060433.XA
Other languages
English (en)
Other versions
CN114340623B (zh
Inventor
张翱
左建平
丁健
谢华
邢莉
何世君
宋子兰
刘雨婷
耿美玉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Publication of CN114340623A publication Critical patent/CN114340623A/zh
Application granted granted Critical
Publication of CN114340623B publication Critical patent/CN114340623B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Abstract

一种嘧啶并[5,4‑b]吡呤化合物或其药学上可接受的盐、溶剂合物或水合物在制备用于治疗包括关节炎症疾病、类风湿性关节炎或系统性红斑狼疮的自身免疫疾病的药物中的用途。所述化合物对类风湿关节炎及以骨破坏和骨侵蚀为病理特征的关节炎症疾病和系统性红斑狼疮有治疗作用。
Figure DDA0003520912690000011

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202080060433.XA 2019-08-29 2020-08-28 嘧啶并[5,4-b]吡呤化合物的制药用途 Active CN114340623B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910807649 2019-08-29
CN2019108076497 2019-08-29
PCT/CN2020/112019 WO2021037188A1 (zh) 2019-08-29 2020-08-28 嘧啶并[5,4-b]吡呤化合物的制药用途

Publications (2)

Publication Number Publication Date
CN114340623A true CN114340623A (zh) 2022-04-12
CN114340623B CN114340623B (zh) 2023-11-17

Family

ID=74683345

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080060433.XA Active CN114340623B (zh) 2019-08-29 2020-08-28 嘧啶并[5,4-b]吡呤化合物的制药用途

Country Status (2)

Country Link
CN (1) CN114340623B (zh)
WO (1) WO2021037188A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114478547A (zh) * 2020-10-23 2022-05-13 上海润石医药科技有限公司 固体形式的布鲁顿酪氨酸激酶抑制剂化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107213149A (zh) * 2017-06-07 2017-09-29 南开大学 青蒿素类衍生物在制备治疗或辅助治疗自身免疫性甲状腺疾病药物中的用途
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180298104A1 (en) * 2015-04-22 2018-10-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of th17 mediated diseases
JP7164203B2 (ja) * 2017-02-08 2022-11-01 中国医▲薬▼研究▲開▼▲発▼中心有限公司 ピロロ芳香族複素環化合物及びその製造方法並びに医薬用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
CN107213149A (zh) * 2017-06-07 2017-09-29 南开大学 青蒿素类衍生物在制备治疗或辅助治疗自身免疫性甲状腺疾病药物中的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
YU XUE等: "Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton\'s Tyrosine Kinase Inhibitors", 《JOURNAL OF MEDICINIAL CHEMISTRY》, vol. 61, no. 10, pages 4608 - 4627, XP055745992, DOI: 10.1021/acs.jmedchem.8b00441 *
YU-TING LIU等: "A novel tricyclic BTK inhibitor suppresses B cell responses and osteoclastic bone erosion in rheumatoid arthritis", 《ACTA PHARMACOL SIN.》, vol. 42, no. 10, pages 1653 - 1664, XP037570969, DOI: 10.1038/s41401-020-00578-0 *

Also Published As

Publication number Publication date
CN114340623B (zh) 2023-11-17
WO2021037188A1 (zh) 2021-03-04

Similar Documents

Publication Publication Date Title
KR101130380B1 (ko) 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도
AU2001295986B2 (en) Nitrogenous aromatic ring compounds
CN105085474B (zh) 鲁顿酪氨酸激酶抑制剂
CN105524058B (zh) 吡唑并[1,5‑a]吡啶类化合物及其应用
JP7210540B2 (ja) 血漿カリクレインの阻害剤およびその使用
HUE034347T2 (en) N-heteroaryl compounds with a cyclic bridge unit for the treatment of parasitic diseases
CN103974950A (zh) 作为ccr(4)拮抗剂的取代的苯并咪唑类和苯并吡唑类
RU2720810C2 (ru) Соли производного хиназолина и способ их получения
CN107266425A (zh) 作为ccr9拮抗剂的吡唑‑1‑基苯磺酰胺
CN111712491B (zh) 四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途
WO2017219915A1 (zh) 一种腺嘌呤衍生物的膦酸酯前药及其在医药上的应用
JP2022506442A (ja) トリフルオロメチル置換スルファミド系選択的ｂｃｌ－２阻害剤
CN112979679A (zh) 具有大环结构的含氟并杂环衍生物及其用途
CN109721605A (zh) 一种免疫细胞迁徙抑制剂
CN114340623A (zh) 嘧啶并[5,4-b]吡呤化合物的制药用途
CN115197207B (zh) 一类四氢-γ-咔啉类衍生物、其药物组合物及应用
CN102827160B (zh) PI3K或PI3K/m-TOR通路抑制剂及其在药学中的用途
CN108017639B (zh) Ido抑制剂及其制备方法和应用
CN112209933B (zh) 含有4-氮杂螺庚烷的btk抑制剂
CN115028646B (zh) 一种含氮杂环类化合物、制备方法及在抗肿瘤制剂中的应用
CN109553604A (zh) 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
WO2022152140A1 (zh) 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途
CN110950773B (zh) 联苯二酚酰胺衍生物及其作为抗癌药物的应用
EP4091670A1 (en) Crystal of imidazopyridinone compound or salt thereof
CN112424185B (zh) 含苯环的化合物、其制备方法及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant